company background image
NGM

NGM Biopharmaceuticals NasdaqGS:NGM Stock Report

Last Price

US$5.37

Market Cap

US$438.9m

7D

-2.0%

1Y

-70.7%

Updated

27 Nov, 2022

Data

Company Financials +
NGM fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

NGM Stock Overview

NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer.

NGM Biopharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for NGM Biopharmaceuticals
Historical stock prices
Current Share PriceUS$5.37
52 Week HighUS$19.14
52 Week LowUS$2.92
Beta1.22
1 Month Change12.34%
3 Month Change-63.81%
1 Year Change-70.72%
3 Year Change-67.42%
5 Year Changen/a
Change since IPO-63.47%

Recent News & Updates

Recent updates

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

Jun 15
Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

Analysts Are Betting On NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) With A Big Upgrade This Week

May 09
Analysts Are Betting On NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) With A Big Upgrade This Week

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

Feb 21
Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

We're Hopeful That NGM Biopharmaceuticals (NASDAQ:NGM) Will Use Its Cash Wisely

Nov 08
We're Hopeful That NGM Biopharmaceuticals (NASDAQ:NGM) Will Use Its Cash Wisely

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

Jul 09
Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Mar 06
NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year

We're Not Very Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn Rate

Mar 02
We're Not Very Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn Rate

Update: NGM Biopharmaceuticals (NASDAQ:NGM) Stock Gained 56% In The Last Year

Jan 26
Update: NGM Biopharmaceuticals (NASDAQ:NGM) Stock Gained 56% In The Last Year

Here's What NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) Shareholder Ownership Structure Looks Like

Dec 22
Here's What NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) Shareholder Ownership Structure Looks Like

Have Insiders Been Selling NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Shares?

Nov 26
Have Insiders Been Selling NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Shares?

Shareholder Returns

NGMUS PharmaceuticalsUS Market
7D-2.0%1.6%1.3%
1Y-70.7%9.9%-18.5%

Return vs Industry: NGM underperformed the US Pharmaceuticals industry which returned 9.9% over the past year.

Return vs Market: NGM underperformed the US Market which returned -18.5% over the past year.

Price Volatility

Is NGM's price volatile compared to industry and market?
NGM volatility
NGM Average Weekly Movement23.3%
Pharmaceuticals Industry Average Movement11.0%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: NGM is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 23% a week.

Volatility Over Time: NGM's weekly volatility has increased from 14% to 23% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2007225David Woodhousehttps://www.ngmbio.com

NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company’s product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase IIb clinical trials for use in the treatment of type 2 diabetes and NASH. Its products under development also comprise NGM120, an antagonist antibody that binds GFRAL that is in Phase I/II clinical trials; NGM621, an immunoglobulin 1 monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy; NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced solid tumors; and NGM831 and NGM438 for the treatment of advanced solid tumors.

NGM Biopharmaceuticals, Inc. Fundamentals Summary

How do NGM Biopharmaceuticals's earnings and revenue compare to its market cap?
NGM fundamental statistics
Market CapUS$438.87m
Earnings (TTM)-US$153.46m
Revenue (TTM)US$58.11m

7.6x

P/S Ratio

-2.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
NGM income statement (TTM)
RevenueUS$58.11m
Cost of RevenueUS$173.07m
Gross Profit-US$114.96m
Other ExpensesUS$38.50m
Earnings-US$153.46m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.88
Gross Margin-197.83%
Net Profit Margin-264.09%
Debt/Equity Ratio0%

How did NGM perform over the long term?

See historical performance and comparison